Search ARM

AavantiBio is a preclinical-stage biopharmaceutical company committed to developing and commercializing novel gene transfer and gene editing therapies for the treatment of rare and ultra-rare genetic diseases. The Company is rapidly building a diverse portfolio of gene transfer and gene editing therapies to target debilitating genetic diseases for which the unmet medical need is high and for which there are typically no approved therapies treating the underlying disease. Headquartered in Cambridge, MA with an additional location in Gainesville, FL.

Contact AavantiBio
Visit Website